New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Treatment & Care \ Treatment \ Drugs \ Lax101 \ Human \ Updates
  HD Lighthouse Editors Comment: LAX-101, pure ethyl eicosapentaenoate (EPA), (EPA Sources) is in trial for the treatment of HD. LAX-101 is manufactured by Laxdale in the UK. Amarin is the distributor in the US. --Jerry


Posted to HDLighthouse:29-Oct-01
HDL Update: LAX-101 Presentations


Rick Stewart, CEO of Amarin, presented his view of the Company's future at the Salomon Smith Barney 2001 Healthcare Conference at the Plaza Hotel, NY on October 29.

Presention on Line:
The entire presentation is available on line at www.veracast.com/clientaccess/ssb/healthcare-2001/54102435.cfm . You will have to listen for while to get the latest information on LAX-101.

The following are the HD relevant slides from the presentation.

Slide 20

Slide 21:

Slide 21: Double blind phase 2 trial. The vertical axis is the UHDRS score. Zero is no impairment. HD patients on plecebo declined 11 units on the UHDRS. HD patients taking LAX-101 improved 4 units on the UHDRS from the start to end of the trial. Compaired to the plecebo they were improved by 15 units. Spectacular, considering that a UHDRS of 60 represents a moderately disabled patient.

Amarin on the Web

Source: Rick Stewart, CEO of Amarin, presented his view of the Company's future at the Salomon Smith Barney 2001 Healthcare Conference at the Plaza Hotel, NY on October 29.

Read the HDAC/HDLighthouse Forum. Post your comments
   
 

Amarin Phase III LAX-101 Huntington Trial
Near term focus is to maintain progress with LAX-101 for Huntington's disease. We expect an additional U.S. Phase III clinical ...
Jerry Lampson
Posted to HDL: 25 Mar 2004

LAX-101 Additional Phase 3 Trials
LAX-101 is a novel and proprietary product being developed for treatment of the symptoms of Huntington's Disease (HD). LAX-101 has ...
Jerry Lampson
Posted to HDL: 03 Feb 2003

Amarin Readies LAX-101 Launch
Amarin announced today that it has completed a private placement of 6,093,727 ordinary shares to a group of accredited investors ...
Adapted from Amarin press release by Jerry Lampson
Posted to HDL: 28 Jan 2003

$500,000,000 Market For Huntingtons' Disease Treatment
Fast track approval of LAX-101 for the treatment of Huntington's disease. Market for LAX-100 estimated at $500,000,000 ... ...
Adapted www.marketwatch.com by Jerry Lampson
Posted to HDL: 04 Dec 2002

LAX-101 AND HUNTINGTON'S DISEASE: QUESTIONS AND ANSWERS
Questions and answers about LAX-101, the first statistically significant treatment for Huntington's disease in phase 3 clinical trials. ... ...
Crispin Bennett PhD
Posted to HDL: 04 Nov 2002

LAX-101 Study Results in Huntington's Disease
Amarin Corporation Announces Encouraging Preliminary Results of LAX-101 Pivotal Study in Huntington's Disease ... ...
Crispin Bennett PhD, Research Information Manager, Laxdale Ltd.
Posted to HDL: 28 Oct 2002

**** HD Treatment LAX101 To Be Available
We knew it all along. HD is a treatable condition. LAX101 is expected be available in the first half of ...
From HDL contributor Ron Hartley 17Jun02
Posted to HDL: 17 Jun 2002

****LAX-101 NPL's Breakthrough
LAX-101 and NPLs Demonstrate Benefit in the Treatment of Huntington's Disease in Separate Phase II Studies..Monash study was halted on ...
Amarin Press Release
Posted to HDL: 23 Jan 2002

LAX-101 Presentation
LAX-101, pure ethyl eicosapentaenoate (EPA), is in trial for the treatment of HD. LAX-101 is manufactured by Laxdale in the ...
Rick Stewart, CEO of Amarin, Salomon Smith Barney 2001 Healthcare Conference
Posted to HDL: 21 Sep 2001

LAX-101 Trial, The trial is now up and running
We at Laxdale follow with great interest all that is posted on the HD Lighthouse Website. We thought you would ...
Crispin Bennett, PhD Research Information Manager 30-May-2001
Posted to HDL: 30 May 2001
[an error occurred while processing this directive]

Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org